Results 151 to 160 of about 118,861 (266)

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1604-1613, June 2026.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Hyperlipidaemia - a risk factor for femoral head osteonecrosis (Legg-Calvè-Perthes-Like disease) in children with AIDS: case report

Brazilian Journal of Infectious Diseases
Although treatment of children infected with HIV with protease inhibitors has improved the survival of these patients, various adverse side effects have been reported, including metabolic abnormalities, such as hyperlipidaemia.
Paula Aguiar de Aragão, Renata B. P. Lemos, Maria Zilda Aquino, Heloísa Helena Souza Marques   +3 more
doaj   +1 more source

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization [PDF]

, 2015
Current guidelines recommend treatment optimization in virologically suppressed patients through switching/ simplification strategies to minimize long-term toxicities and improve adherence. The assessment of inflammation/ coagulation profiles may support
FALASCA, FRANCESCA, FANTAUZZI, Alessandra, Floridia, Marco, MEZZAROMA, Ivano, SPANEDDA, Pierpaolo, TURRIZIANI, Ombretta, VULLO, Vincenzo   +6 more
core  

PACS2 Alleviates Sepsis‐Induced Myopathy by Activating ERK–MAPK Signalling Pathway to Suppress ER‐Phagy

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Sepsis‐induced myopathy (SIM) is a common and life‐threatening complication, but its underlying mechanisms remain poorly understood. PACS2, a key resident protein at mitochondria‐associated endoplasmic reticulum membranes (MAMs), regulates ER homeostasis under various pathological conditions.
Xuexin Li, Zu‐an Shi, Fei He, Guo Mu, Feixiang Wang, Bowen Sun, Xiaobin Wang, Li Liu   +7 more
wiley   +1 more source

Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq, Doni Dermawan, Samir Chtita   +2 more
wiley   +1 more source

An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The approval requirements in new regions that do not require domestic clinical data and the clinical data evaluation of multi‐regional clinical trials (MRCTs) and foreign clinical trials (FCTs) in the Japanese approval review processes for antimicrobial medicines were explored.
Rumiko Shimazawa, Masayuki Ikeda
wiley   +1 more source

Mitochondrial DNA: A Key Alarmin Igniting the Inflammasome Fire in Health and Disease

Immunology, Volume 178, Issue 2, Page 218-230, June 2026.
This review illustrates how mitochondrial DNA, released under cellular stress, acts as a key alarmin that ignites innate immune sensors, particularly inflammasomes and the cGAS‐STING pathway. This paper details how this sustained “inflammasome fire” fuels the progression of diverse inflammatory diseases, including neurodegeneration and metabolic ...
Woo Hyun Park
wiley   +1 more source

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

Low‐Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Achieving hepatitis C virus (HCV) elimination requires innovative paradigms that overcome barriers to treatment, such as requiring pre‐treatment elastography or phlebotomy‐based fibrosis assessment. To identify patients at low risk of advanced fibrosis or decompensated cirrhosis within our HCV treatment programme, we developed and ...
Hunter Spencer, Barbara Brumbach, Anna Geduldig, Lisa Nelson, Andrew Seaman   +4 more
wiley   +1 more source

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

Advanced Functional Materials, Volume 36, Issue 36, 4 May 2026.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley, Paul G. Ayoub, Vrishti Sinha, Colin Juett, Alicia Sanoyca, Emily C. Duggan, Lindsay E. Lathrop, Priyanka Bhatt, Kevin Coote, Beate Illek, Brigitte N. Gomperts, Donald B. Kohn, Steven J. Jonas   +12 more
wiley   +1 more source